Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in GBA1, the gene encoding lysosomal glucocerebrosidase, are the most frequent known genetic risk factor for Parkinson's disease. Reduced glucocerebrosidase and α-synuclein accumulation are directly related in cell models of Parkinson's disease. We investigated relationships between Parkinson's disease-specific glucocerebrosidase deficits, glucocerebrosidase-related pathways, and α-synuclein levels in brain tissue from subjects with sporadic Parkinson's disease without GBA1 mutations. Brain regions with and without a Parkinson's disease-related increase in α-synuclein levels were assessed in autopsy samples from subjects with sporadic Parkinson's disease (n = 19) and age- and post-mortem delay-matched controls (n = 10). Levels of glucocerebrosidase, α-synuclein and related lysosomal and autophagic proteins were assessed by western blotting. Glucocerebrosidase enzyme activity was measured using a fluorimetric assay, and glucocerebrosidase and α-synuclein messenger RNA expression determined by quantitative polymerase chain reaction. Related sphingolipids were analysed by mass spectrometry. Multivariate statistical analyses were performed to identify differences between disease groups and regions, with non-parametric correlations used to identify relationships between variables. Glucocerebrosidase protein levels and enzyme activity were selectively reduced in the early stages of Parkinson's disease in regions with increased α-synuclein levels although limited inclusion formation, whereas GBA1 messenger RNA expression was non-selectively reduced in Parkinson's disease. The selective loss of lysosomal glucocerebrosidase was directly related to reduced lysosomal chaperone-mediated autophagy, increased α-synuclein and decreased ceramide. Glucocerebrosidase deficits in sporadic Parkinson's disease are related to the abnormal accumulation of α-synuclein and are associated with substantial alterations in lysosomal chaperone-mediated autophagy pathways and lipid metabolism. Our data suggest that the early selective Parkinson's disease changes are likely a result of the redistribution of cellular membrane proteins leading to a chronic reduction in lysosome function in brain regions vulnerable to Parkinson's disease pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, loss‐of‐function mutations in GBA disrupt the autophagic flux and lead to the aggregation of SNCA/α‐synuclein (Murphy et al, 2014).”
From Autophagy in major human diseases (2021) · cites this paper as Murphy et al, 2014
Citations
Cites
1 retracted
Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 367
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
How to Interpret LC3 Immunoblotting
Mizushima, N., & Yoshimori, T. (2007) · Autophagy · doi:10.4161/auto.4600 · Cited by 2,669
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationImpaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Lysosomal membrane permeabilization in cell death
Boya, P., & Kroemer, G. (2008) · Oncogene · doi:10.1038/onc.2008.310 · Cited by 1,426
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Self-citation
Research works printed but not linked: 1
- Stone, 2000, Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease, Hum Mutat, 15, 181, 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S · DOI · Paper page
Cited by
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
The coming of age of chaperone-mediated autophagy
Kaushik, S., & Cuervo, A. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0001-6 · Cited by 1,407
Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities
Menzies, F. M., Fleming, A., Caricasole, A., Bento, C. F., Andrews, S. P., Ashkenazi, A., Füllgrabe, J., Jackson, A., Jimenez Sanchez, M., Karabiyik, C., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.01.022 · Cited by 1,134
“In PD patients without GBA mutations, the levels and activity of the enzyme are decreased in brain areas with increased α-syn levels in early disease stages (Mazzulli et al., 2011; Murphy et al., 2014).”
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020441 · Cited by 868
“(A) Normally, GCase interacts with its substrate glucosylceramide (GlcCer) as well as monomers of α-synuclein in lysosomes, facilitating the breakdown of both at acidic pH; (B) Mutated GCase or decreased levels of GCase result in a slowdown of α-synuclein degradation and a gradual build up of GlcCer, with the formatio…”
BackgroundCompromised autophagy and neurodegenerative diseases
Menzies, F. M., Fleming, A., & Rubinsztein, D. C. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3961 · Cited by 851
Lysosomes as a therapeutic target
Bonam, S. R., Wang, F., & Muller, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0036-1 · Cited by 759
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
“-syn pathology lysosomal function PD risk in single mutant GBA allele carriers Balducci et al., 2007; Sidransky et a.l, 2009 ; Sardi et al., 2013; Murphy et al., 2014 ; Parnetti et al., 2014.”
The different autophagy degradation pathways and neurodegeneration
Fleming, A., Bourdenx, M., Fujimaki, M., Karabiyik, C., Krause, G. J., Lopez, A., Martín-Segura, A., Puri, C., Scrivo, A., Skidmore, J., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.01.017 · Cited by 480
The Role of Autophagy in Parkinson's Disease
Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M., & Klionsky, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009357 · Cited by 458
Pang, S. Y.-Y., Ho, P. W.-L., Liu, H.-F., Leung, C.-T., Li, L., Chang, E. E. S., Ramsden, D. B., & Ho, S.-L. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0165-9 · Cited by 427
Genetics and Pathogenesis of Parkinson's Syndrome
Ye, H., Robak, L. A., Yu, M., Cykowski, M., & Shulman, J. M. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-034145 · Cited by 416
“Glucocerebrosidase activity may also be reduced in idiopathic PD among individuals without GBA variants (146, 147).”
BackgroundGlucocerebrosidase activity in Parkinson’s disease with and without GBA mutations
Alcalay, R. N., Levy, O. A., Waters, C. H., Fahn, S., Ford, B., Kuo, S.-H., Mazzoni, P., Pauciulo, M. W., Nichols, W. C., Gan-Or, Z., et al. (2015) · Brain · doi:10.1093/brain/awv179 · Cited by 392
“…enzymatic activity has been previously reported in Parkinson’s disease and Lewy body dementia in CSF (Balducci et al ., 2007; Parnetti et al ., 2009, 2014) and in two brain autopsy studies (Gegg et al ., 2012; Murphy et al ., 2014), findings which are consistent with our observation.”
ResultMullin, S., Smith, L., Lee, K., D’Souza, G., Woodgate, P., Elflein, J., Hällqvist, J., Toffoli, M., Streeter, A., Hosking, J., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4611 · Cited by 356
Wang, R., Li, B., Lam, S. M., & Shui, G. (2020) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.009 · Cited by 330
Sphingolipids: membrane microdomains in brain development, function and neurological diseases
Olsen, A. S. B., & Færgeman, N. J. (2017) · Open Biology · doi:10.1098/rsob.170069 · Cited by 311
“A reduced activity of GCase has been found in the brain of PD patients [159,160].”
BackgroundGlucocerebrosidase and its relevance to Parkinson disease
Do, J., McKinney, C., Sharma, P., & Sidransky, E. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0336-2 · Cited by 300
Self-citationDavis, M. Y., Trinh, K., Thomas, R. E., Yu, S., Germanos, A. A., Whitley, B. N., Sardi, S. P., Montine, T. J., & Pallanck, L. J. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005944 · Cited by 293
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Moors, T. E., Hoozemans, J. J. M., Ingrassia, A., Beccari, T., Parnetti, L., Chartier-Harlin, M.-C., & van de Berg, W. D. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0154-3 · Cited by 278
“For cathepsin D, increased [56] and decreased [52] activities were reported in the PD cingulate cortex and SN, respectively, while no changes were found in the frontal cortex [62].”
BackgroundDzamko, N., Gysbers, A., Perera, G., Bahar, A., Shankar, A., Gao, J., Fu, Y., & Halliday, G. M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1648-8 · Cited by 273
“1e shows group comparisons, also shown previously [29]) and TLR2 levels (Fig.”
BackgroundMethodSelf-citationGBA Variants and Parkinson Disease: Mechanisms and Treatments
Smith, L., & Schapira, A. H. V. (2022) · Cells · doi:10.3390/cells11081261 · Cited by 256
Autophagy and Alpha‐Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies
Xilouri, M., Brekk, O. R., & Stefanis, L. (2016) · Movement Disorders · doi:10.1002/mds.26477 · Cited by 261
Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease
Gan-Or, Z., Dion, P. A., & Rouleau, G. A. (2015) · Autophagy · doi:10.1080/15548627.2015.1067364 · Cited by 260
Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
Alecu, I., & Bennett, S. A. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00328 · Cited by 258
“Moreover, it is only the moderate reductions (as are seen in PD and DLB,) and not the severe reductions in GCase activity (as are observed Gaucher disease), that increase α-syn levels in vitro as detected in post-mortem PD brain tissue (Murphy et al., 2014; Kim et al., 2018).”
BackgroundHDL and cholesterol handling in the brain
Vitali, C., Wellington, C. L., & Calabresi, L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu148 · Cited by 254
The Role of Lipids in Parkinson’s Disease
Xicoy, H., Wieringa, B., & Martens, G. J. M. (2019) · Cells · doi:10.3390/cells8010027 · Cited by 250
“Reduced levels of ceramide may be associated with α-synuclein accumulation [356,357].”
BackgroundResultTherapeutic approaches to target alpha-synuclein pathology
Brundin, P., Dave, K. D., & Kordower, J. H. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.003 · Cited by 242
“These mutations have been reported to reduce GCase activity in PD brain tissue (Murphy et al., 2014) and cerebrospinal fluid (Parnetti et al.”
Magalhaes, J., Gegg, M. E., Migdalska-Richards, A., Doherty, M. K., Whitfield, P. D., & Schapira, A. H. V. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw185 · Cited by 234
Impaired lysosomal acidification triggers iron deficiency and inflammation in vivo
Yambire, K. F., Rostosky, C., Watanabe, T., Pacheu-Grau, D., Torres-Odio, S., Sanchez-Guerrero, A., Senderovich, O., Meyron-Holtz, E. G., Milosevic, I., Frahm, J., et al. (2019) · eLife · doi:10.7554/elife.51031 · Cited by 232
“For example, many of 698 the genes that cause inherited Parkinson’s disease are associated either with mitochondria 699 or lysosomes/autophagy, and therefore the primarily-damaged organelle is likely to promote 700 the secondary impairment of the other.”
BackgroundInfluentialAflaki, E., Borger, D. K., Moaven, N., Stubblefield, B. K., Rogers, S. A., Patnaik, S., Schoenen, F. J., Westbroek, W., Zheng, W., Sullivan, P., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0636-16.2016 · Cited by 227
“Moreover, patients with sporadic PD without GBA1 mutations also have reduced GCase activity that is associated with increased -syn levels (Murphy et al., 2014).”
BackgroundSelf-citationStructure, function and toxicity of alpha‐synuclein: the Bermuda triangle in synucleinopathies
Villar‐Piqué, A., Lopes da Fonseca, T., & Outeiro, T. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13249 · Cited by 218
Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide
Zunke, F., Moise, A. C., Belur, N. R., Gelyana, E., Stojkovska, I., Dzaferbegovic, H., Toker, N. J., Jeon, S., Fredriksen, K., & Mazzulli, J. R. (2018) · Neuron · doi:10.1016/j.neuron.2017.12.012 · Cited by 223
“…have been documented in sporadic PD patients expressing wild-type (WT) GCase (Alcalay et al., 2015; Gegg et al., 2012; Mazzulli et al., 2011; Murphy et al., 2014; Rocha et al., 2015), possibly through a-syn accumulation (Mazzulli et al., 2011; Yap et al., 2013), suggesting a more general…”
Alpha-Synuclein Function and Dysfunction on Cellular Membranes
Snead, D., & Eliezer, D. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.4.292 · Cited by 223
“Reduced GCase with synuclein accumulation has been observed in PD brain tissue as well [246].”
BackgroundInflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222
Self-citationGlucocerebrosidase and Parkinson disease: Recent advances
Schapira, A. H. V. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.03.013 · Cited by 219
“An analysis of Lewy body density load in PD brain found an inverse relationship with GCase activity (Murphy et al., 2014).”
Progressive decline of glucocerebrosidase in aging and Parkinson's disease
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hallett, P., & Isacson, O. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.177 · Cited by 210
“These patients usually develop the disease earlier and are associated with more advanced a-synuclein pathology.(8,11) The motor impairments among GBA1 PD patients usually occur 6–7 years earlier in comparison to nonGBA1 PD patients.”
BackgroundAutophagy in Neurodegenerative Diseases: A Hunter for Aggregates
Park, H., Kang, J.-H., & Lee, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093369 · Cited by 207
Kim, S., Wong, Y. C., Gao, F., & Krainc, D. (2021) · Nature Communications · doi:10.1038/s41467-021-22113-3 · Cited by 199
Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease
Zeng, X.-S., Geng, W.-S., Jia, J.-J., Chen, L., & Zhang, P.-P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00109 · Cited by 193
“A significant and progressive reduction in GCase 1 activity and protein levels is also observed in the brains and cerebrospinal fluid of PD patients (Murphy et al., 2014; Rocha et al., 2015; Parnetti et al., 2017).”
BackgroundImpaired intracellular trafficking defines early Parkinson's disease
Hunn, B. H. M., Cragg, S. J., Bolam, J. P., Spillantini, M.-G., & Wade-Martins, R. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.12.009 · Cited by 184
Lysosomal Dysfunction and α‐Synuclein Aggregation in Parkinson's Disease: Diagnostic Links
Moors, T., Paciotti, S., Chiasserini, D., Calabresi, P., Parnetti, L., Beccari, T., & van de Berg, W. D. J. (2016) · Movement Disorders · doi:10.1002/mds.26562 · Cited by 173
Is Parkinson’s disease a lysosomal disorder?
Klein, A. D., & Mazzulli, J. R. (2018) · Brain · doi:10.1093/brain/awy147 · Cited by 172
Gaucher disease: Progress and ongoing challenges
Mistry, P. K., Lopez, G., Schiffmann, R., Barton, N. W., Weinreb, N. J., & Sidransky, E. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.11.006 · Cited by 165
Self-citationMitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders
Plotegher, N., & Duchen, M. R. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.003 · Cited by 161
“Lastly, for reasons that remain unclear, GCase activity is reduced in the brains of patients with sporadic PD [15].”
BackgroundHuebecker, M., Moloney, E. B., van der Spoel, A. C., Priestman, D. A., Isacson, O., Hallett, P. J., & Platt, F. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0339-z · Cited by 165
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Spiro, A. S., Furuta, A., Cooper, A., Garner, B., Kabuta, T., & Halliday, G. M. (2015) · Movement Disorders · doi:10.1002/mds.26141 · Cited by 164
“Although assessment of postmortem PD tissue is unable to address cellular changes occurring before symptom onset, the PD cases examined in this study were mostly Braak stage IV, the earliest disease stage with substantial biochemical asynuclein changes in frontal cortical regions that precede the structural a-synuclei…”
BackgroundMethodResultInfluentialSelf-citationThe Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease
Aflaki, E., Westbroek, W., & Sidransky, E. (2017) · Neuron · doi:10.1016/j.neuron.2017.01.018 · Cited by 159
“Evaluating brain bank samples, it was found that even subjects with idiopathic PD have decreased levels of GCase on western blots (Gegg et al., 2012; Murphy et al., 2014; Rocha et al., 2015).”
Self-citationGlucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hayes, M. A., Beagan, J., McLean, J. R., Izen, S. C., Perez-Torres, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.009 · Cited by 160
“Several other autophagy–lysosomal related proteins, including ATP13A2 and LAMP-2A, are downregulated in dopaminergic neurons of sporadic PD patients (Decressac et al., 2013; Dehay et al., 2012; Gegg et al., 2012; Murphy et al., 2014).”
BackgroundResultInfluentialThe cell biology of Parkinson’s disease
Panicker, N., Ge, P., Dawson, V. L., & Dawson, T. M. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202012095 · Cited by 159
Sanchez-Martinez, A., Beavan, M., Gegg, M. E., Chau, K.-Y., Whitworth, A. J., & Schapira, A. H. V. (2016) · Scientific Reports · doi:10.1038/srep31380 · Cited by 158
Glycosphingolipids and Neuroinflammation in Parkinson’s Disease
Belarbi, K., Cuvelier, E., Bonte, M.-A., Desplanque, M., Gressier, B., Devos, D., & Chartier-Harlin, M.-C. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00408-1 · Cited by 155
Moors, T. E., Paciotti, S., Ingrassia, A., Quadri, M., Breedveld, G., Tasegian, A., Chiasserini, D., Eusebi, P., Duran-Pacheco, G., Kremer, T., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1090-0 · Cited by 150
“Reduced GBA expression in the SN has previously been reported [16], while another study reported a trend for decreased GBA mRNA expression in the anterior cingulate cortex [17].”
GBA-Associated Parkinson’s Disease and Other Synucleinopathies
Gan‐Or, Z., Liong, C., & Alcalay, R. N. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0860-4 · Cited by 167
Chiasserini, D., Paciotti, S., Eusebi, P., Persichetti, E., Tasegian, A., Kurzawa-Akanbi, M., Chinnery, P. F., Morris, C. M., Calabresi, P., Parnetti, L., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0010-2 · Cited by 148
“Our results confirm previous reports on the deregulation of GCase in PD [6,7].”
BackgroundResultInfluentialDysfunction of Cellular Proteostasis in Parkinson’s Disease
Lehtonen, Š., Sonninen, T.-M., Wojciechowski, S., Goldsteins, G., & Koistinaho, J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00457 · Cited by 147
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult
Henderson, M. X., Sedor, S., McGeary, I., Cornblath, E. J., Peng, C., Riddle, D. M., Li, H. L., Zhang, B., Brown, H. J., Olufemi, M. F., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.004 · Cited by 146
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Graham, A.-R., Brown, E., McLean, J. R., Hayes, M. A., Beagan, J., Izen, S. C., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6307 · Cited by 145
“Deficits in autophagy–lysosomal degradation are implicated in the pathophysiology of PD (14, 40).”
BackgroundRecent advances in the diagnosis and management of Gaucher disease
Gary, S. E., Ryan, E., Steward, A., & Sidransky, E. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1445524 · Cited by 149
Self-citationSilveira, C. R. A., MacKinley, J. D., Coleman, K. K. L., Li, Z., Finger, E. C., Bartha, R., Morrow, S. A., Wells, J., BORRIE, M. J., Tirona, R. G., et al. (2019) · BMC Neurology · doi:10.1186/s12883-019-1252-3 · Cited by 149
No evidence for substrate accumulation in Parkinson brains with GBA mutations
Gegg, M. E., Sweet, L., Wang, B. H., Shihabuddin, L. S., Sardi, S. P., & Schapira, A. H. V. (2015) · Movement Disorders · doi:10.1002/mds.26278 · Cited by 136
“GCase activity also has been reported to be decreased in the anterior cingulate cortex of sporadic PD brains.(5) Defects in the autophagy–lysosomal pathway (ALP) are implicated in the accumulation/aggregation of a-synuclein and mitochondrial dysfunction observed in PD.”
BackgroundAutophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics
Senkevich, K., & Gan-Or, Z. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.11.015 · Cited by 132
The Emerging Role of the Lysosome in Parkinson’s Disease
Navarro-Romero, A., Montpeyó, M., & Martinez-Vicente, M. (2020) · Cells · doi:10.3390/cells9112399 · Cited by 135
“In contrast, others reported no changes in SN [116] or even an increase in the anterior cingulate cortex in early-stage PD patients [119].”
BackgroundResultBrockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01276-6 · Cited by 138
Du, T.-T., Wang, L., Duan, C.-L., Lu, L.-L., Zhang, J.-L., Gao, G., Qiu, X.-B., Wang, X.-M., & Yang, H. (2015) · Autophagy · doi:10.1080/15548627.2015.1086055 · Cited by 129
“Reduced GBA protein expression and activity are detected in the brains of PD patients carrying GBA mutations as well as in sporadic cases;(15) in the latter, ceramide is reduced in brain regions that accumulate SNCA and exhibit GBA deficiency.(38) The results of this study present the first evidence that the mechanist…”
BackgroundKeatinge, M., Bui, H., Menke, A., Chen, Y.-C., Sokol, A. M., Bai, Q., Ellett, F., Da Costa, M., Burke, D., Gegg, M., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv369 · Cited by 129
“GCase activity and alpha-synuclein levels (9,16,32).”
Exercise activates lysosomal function in the brain through AMPK‐SIRT1‐TFEB pathway
Huang, J., Wang, X., Zhu, Y., Li, Z., Zhu, Y., Wu, J., Qin, Z., Xiang, M., & Lin, F. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13114 · Cited by 129
Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats
Xilouri, M., Brekk, O. R., Polissidis, A., Chrysanthou-Piterou, M., Kloukina, I., & Stefanis, L. (2016) · Autophagy · doi:10.1080/15548627.2016.1214777 · Cited by 126
Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs
Aflaki, E., Stubblefield, B. K., Maniwang, E., Lopez, G., Moaven, N., Goldin, E., Marugan, J., Patnaik, S., Dutra, A., Southall, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008659 · Cited by 126
“Because patients with Parkinson’s disease have been shown to have decreased levels of glucocerebrosidase in certain brain regions (9, 10), such chaperones could potentially be useful in the treatment of Parkinson’s disease as well.”
BackgroundSelf-citationMorabito, G., Giannelli, S. G., Ordazzo, G., Bido, S., Castoldi, V., Indrigo, M., Cabassi, T., Cattaneo, S., Luoni, M., Cancellieri, C., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.004 · Cited by 126
Moloney, E. B., Moskites, A., Ferrari, E. J., Isacson, O., & Hallett, P. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.013 · Cited by 124
“, 2015a), and has been associated with driving alpha-synuclein pathology (Mazzulli et al., 2011; Murphy et al., 2014).”
Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease
Atashrazm, F., Hammond, D., Perera, G., Dobson-Stone, C., Mueller, N., Pickford, R., Kim, W. S., Kwok, J. B., Lewis, S. J. G., Halliday, G. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33921-x · Cited by 125
Self-citationThe role of glucocerebrosidase in Parkinson disease pathogenesis
Gegg, M. E., & Schapira, A. H. V. (2018) · The FEBS Journal · doi:10.1111/febs.14393 · Cited by 123
Laperle, A., Sances, S., Yucer, N., Dardov, V. J., Garcia, V. J., Ho, R., Fulton, A., Jones, M. R., Roxas, K., Avalos, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0739-1 · Cited by 132
LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance
Rothaug, M., Zunke, F., Mazzulli, J. R., Schweizer, M., Altmeppen, H., Lüllmann-Rauch, R., Kallemeijn, W. W., Gaspar, P., Aerts, J. M., Glatzel, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405700111 · Cited by 122
“Loss-of-function GBA1 mutations have been associated with a higher risk of developing PD (10), and recent research of autopsy cases of patients with sporadic PD showed reduced GC activity in brain regions with increased α-syn levels (35, 36).”
BackgroundN370S‐GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease
García‐Sanz, P., Orgaz, L., Bueno‐Gil, G., Espadas, I., Rodríguez‐Traver, E., Kulisevsky, J., Gutierrez, A., Dávila, J. C., González‐Polo, R. A., Fuentes, J. M., et al. (2017) · Movement Disorders · doi:10.1002/mds.27119 · Cited by 121
“We have shown that reduced lysosomal GCase1 levels and activity are a result of the retention of N370S GCase1 within the ER, interrupting its cellular traffic, and not to changes in transcription, extending previous studies.(6,7,12,13,38,39) We have shown for the first time reduced GCase1 levels localized in the lysos…”
BackgroundLoss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation
Bae, E.-J., Yang, N. Y., Lee, C.-S., Lee, H.-J., Kim, S., Sardi, S. P., & Lee, S. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.128 · Cited by 133
The Vicious Cycle Between α ‐Synuclein Aggregation and Autophagic‐Lysosomal Dysfunction
Bellomo, G., Paciotti, S., Gatticchi, L., & Parnetti, L. (2019) · Movement Disorders · doi:10.1002/mds.27895 · Cited by 127
“Conversely, lower levels of Cer as well as its altered chain composition have been described in the anterior cingulate cortex of PD patients with respect to controls.(60,102) As a support for this link between Cer and PD, the inhibition of acid ceramidase (encoded by ASAH1) by carmofur resulted in increased Cer levels…”
ResultLysosome and Inflammatory Defects in GBA1‐Mutant Astrocytes Are Normalized by LRRK2 Inhibition
Sanyal, A., DeAndrade, M. P., Novis, H. S., Lin, S., Chang, J., Lengacher, N., Tomlinson, J. J., Tansey, M. G., & LaVoie, M. J. (2020) · Movement Disorders · doi:10.1002/mds.27994 · Cited by 113
“Increasing evidence, however, associates partial GCase loss of function with parkinsonism as heterozygous carriers of GBA1 mutations are at a significantly higher risk of PD.(60-63) Genetic studies show that 5% to 10% of people with PD harbor a GBA1 mutation.”
BackgroundMolecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease
Stojkovska, I., Krainc, D., & Mazzulli, J. R. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2704-y · Cited by 110
“Reduced GCase activity in sporadic or GBA1-PD brain was subsequently confirmed by other groups (Gegg et al. 2012; Murphy et al. 2014; Rocha et al. 2015a) and alterations in GCase maturity were observed in the brains of patients expressing A53T α-syn (Chung et al. 2013).”
Autophagy in neurodegenerative diseases: From pathogenic dysfunction to therapeutic modulation
Martínez‐Vicente, M. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.03.005 · Cited by 122
Role of Autophagy in Parkinson’s Disease
Cerri, S., & Blandini, F. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180226094351 · Cited by 118
Gaetani, L., Paolini Paoletti, F., Bellomo, G., Mancini, A., Simoni, S., Di Filippo, M., & Parnetti, L. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.011 · Cited by 108
Elevated GM3 plasma concentration in idiopathic Parkinson’s disease: A lipidomic analysis
Chan, R. B., Perotte, A. J., Zhou, B., Liong, C., Shorr, E. J., Marder, K. S., Kang, U. J., Waters, C. H., Levy, O. A., Xu, Y., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172348 · Cited by 108
Burbulla, L. F., Jeon, S., Zheng, J., Song, P., Silverman, R. B., & Krainc, D. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6870 · Cited by 112
“Wild-type glucocerebrosidase activation partially rescues pathogenic phenotypes in non–GBA-PD iPSC-derived dopaminergic neurons Our recent studies showed that wild-type GCase enzyme activity was decreased in mutant LRRK2, Parkin, and DJ-1 iPSC-derived dopaminergic neurons (8, 9) and in iPSC-derived dopaminergic neuron…”
Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease
Oeda, T., Umemura, A., Mori, Y., Tomita, S., Kohsaka, M., Park, K., Inoue, K., Fujimura, H., Hasegawa, H., Sugiyama, H., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.027 · Cited by 105
“Several recent researches propose the possibility that the similar mechanism as in PD with GBAmutations exists even in idiopathic PD brain (Alcalay et al., 2015; Chiasserini et al., 2015; Gegg et al., 2012; Murphy et al., 2014).”
BackgroundDysregulation of autophagy and mitochondrial function in Parkinson’s disease
Wang, B., Abraham, N., Gao, G., & Yang, Q. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0065-1 · Cited by 105
“The loss of lysosomal glucocerebrosidase is directly related to reduced lysosomal CMA activity, increased α-synuclein and decreased ceramide, which suggests that compromise in lysosomal function contributes to PD pathology [93].”
BackgroundGlucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine
Blandini, F., Cilia, R., Cerri, S., Pezzoli, G., Schapira, A. H. V., Mullin, S., & Lanciego, J. L. (2018) · Movement Disorders · doi:10.1002/mds.27583 · Cited by 113
“Indeed, GCase deficiency has been described in the brain,(106) cerebrospinal fluid,(107) and blood(108) of sporadic PD patients without GBA1 mutations and correlates with increased α-syn levels.(109)”
Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease
Hallett, P. J., Engelender, S., & Isacson, O. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1532-2 · Cited by 104
“GCase activity is reduced and glycosphingolipid levels are increased, in the brain of PD patients with and without a GBA1 mutation [18, 51, 52] as well as in the brain in aging [18, 53], and seems to be part of an age-induced phenocopy of the genetic haploinsufficiency of GBA1 seen in patients [53].”
BackgroundIron and Neurodegeneration: Is Ferritinophagy the Link?
Biasiotto, G., Lorenzo, D. D., Archetti, S., & Zanella, I. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9473-y · Cited by 109
Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies
Krohn, L., Öztürk, T. N., Vanderperre, B., Ouled Amar Bencheikh, B., Ruskey, J. A., Laurent, S. B., Spiegelman, D., Postuma, R. B., Arnulf, I., Hu, M. T. M., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25629 · Cited by 100
Ambrosi, G., Ghezzi, C., Zangaglia, R., Levandis, G., Pacchetti, C., & Blandini, F. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.008 · Cited by 102
“Reduced GCase activity favors the accumulation of alpha-synuclein in the brain of sporadic PD patients (Murphy et al., 2014).”
Variants associated with Gaucher disease in multiple system atrophy
Mitsui, J., Matsukawa, T., Sasaki, H., Yabe, I., Matsushima, M., Dürr, A., Brice, A., Takashima, H., Kikuchi, A., Aoki, M., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.185 · Cited by 100
Key genes and convergent pathogenic mechanisms in Parkinson disease
Coukos, R., & Krainc, D. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00812-2 · Cited by 127
“In the brains of individuals with sporadic PD, regions with elevated α-synuclein accumulation specifically show diminished GBA1 maturation and activity 114 .”
Helley, M., Pinnell, J. R., Sportelli, C., & Tieu, K. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00177 · Cited by 110
“An increase in α-synuclein expression has also been shown to inhibit GBA activity (Mazzulli et al., 2011; Gegg et al., 2012; Murphy et al., 2014), thus further impairing the clearance of α-synuclein mediated by autophagy.”
BackgroundGlucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications
Balestrino, R., & Schapira, A. H. V. (2018) · The Neuroscientist · doi:10.1177/1073858417748875 · Cited by 95
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease
Avenali, M., Blandini, F., & Cerri, S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00097 · Cited by 104
“These findings partially contradict previous studies that did not report GCase substrate accumulation in the brain of PD patients with heterozygote GBA1 mutations or iPD patients with reduced GCase activity (Murphy et al., 2014; Gegg et al., 2015).”
ResultEstes, R., Lin, B. C., Khera, A., & Davis, M. Y. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.788695 · Cited by 109
“While it is not unexpected that GBA carriers with PD may have lipid metabolism abnormalities, even sporadic PD patients without GBA mutations were observed to have reduced GCase activity in postmortem tissue (Murphy et al., 2014).”
BackgroundMitochondrial dysfunction associated with glucocerebrosidase deficiency
Gegg, M. E., & Schapira, A. H. V. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.006 · Cited by 94
“Another study indicated that GCase protein expression was significantly decreased in the anterior cingulate cortex of sporadic PD brains (Murphy et al., 2014).”
BackgroundInfluentialGenes associated with Parkinson's disease: regulation of autophagy and beyond
Beilina, A., & Cookson, M. R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13266 · Cited by 93
“…reduced glucocerebrosidase protein levels and enzyme activity in a range of affected brain regions in patients with sporadic PD. Supporting this observation GBA protein levels and enzyme activity were selectively reduced in brain regions that accumulate abnormal a-synuclein (Murphy et al. 2014).”
BackgroundAutophagy and Its Impact on Neurodegenerative Diseases: New Roles for TDP-43 and C9orf72
Budini, M., Buratti, E., Morselli, E., & Criollo, A. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00170 · Cited by 106
“This promotes the accumulation of glucocerebroside together with α-synuclein in the brain, thus promoting neurodegeneration (Mazzulli Frontiers in Molecular Neuroscience | www.frontiersin.org 6 May 2017 | Volume 10 | Article 170 et al., 2011; Murphy et al., 2014).”
BackgroundMolecular changes in the postmortem parkinsonian brain
Toulorge, D., Schapira, A. H. V., & Hajj, R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13696 · Cited by 93
Metadata
- Authors
- Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M.
- Affiliations
- UNSW Sydney (AU)
- Neuroscience Research Australia (AU)
- University of Wollongong (AU)
- National Institutes of Health (US)
- Garvan Institute of Medical Research (AU)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-28
- Volume
- 137
- Issue
- 3
- Pages
- 834-848
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3927701
- OpenAlex
- W2144140825
- Cited by
- 475
- References
- 85
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 37 · 2023: 31 · 2022: 39 · 2021: 52 · 2020: 54 · 2019: 49 · 2018: 30 · 2017: 34 · 2016: 42 · 2015: 42 · 2014: 15
- FWCI
- 29.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Figshare (submittedVersion, cc-by)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (R24AA012725, R28AA012725)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, alpha-synuclein, GBA1, sporadic Parkinson's disease, lysosomal dysfunction, chaperone-mediated autophagy, ceramide, sphingolipids, early-stage Parkinson's disease, brain regions, inclusion formation
- MeSH terms
- Aged, Aged, 80 and over, Autophagy, Brain, Female, Glucosylceramidase, Humans, Lysosomes, Male, Mutation, Parkinson Disease, Cohort Studies, Up-Regulation, Case-Control Studies, Molecular Chaperones, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.